Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971–9.
McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5650–9.
Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull. 2011;34:1774–80.
Eckstein N, Röper L, Haas B, Potthast H, Hermes U, Unkrig C, et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. J Exp Clin Cancer Res CR. 2014;33:15.
Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30:591–601.
Dirix L, Rutseart R. Arterial hypertension induced by vascular endothelial growth factor interfering agents: mechanisms and management. Belg J Med Oncol. 2010;4:159–67.
Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract. 2011;2011:816897.
Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens. 2013;27:601–11.
Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell GD. Tyrosine kinase inhibitor-induced hypertension. Curr Oncol Rep. 2018;20:65.
Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007;18:1117.
Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327–38.
Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:1363–9.
Lankhorst S, Kappers MHW, van Esch JHM, Danser AHJ, van den Meiracker AH. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal. 2014;20:135–45.
Alivon M, Giroux J, Briet M, Goldwasser F, Laurent S, Boutouyrie P. Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression. J Hypertens. 2015;33:1310–7.
Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12:409–25.
de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension. 2012;60:607–15.
Kruzliak P, Novák J, Novák M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens. 2014;27:3–13.
Kappers MHW, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675–81.
Kappers MHW, Smedts FMM, Horn T, van Esch JHM, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58:295–302.
Kappers MHW, de Beer VJ, Zhou Z, Danser AHJ, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59:151–7.
Nagasawa T, Hye Khan MA, Imig JD. Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol. 2012;39:454–61.
Grisk O, Koenen A, Meissner T, Donner A, Braun D, Steinbach A, et al. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption. J Hypertens. 2014;32:2199–210 discussion 2110.
Isobe T, Komatsu R, Honda M, Kuramoto S, Shindoh H, Tabo M. Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats. J Toxicol Sci. 2014;39:237–42.
Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H, et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol. 2011;45:804–8.
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.
Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753–64.
Terrett NK, Bell AS, Brown D, Ellis P. Sildenafil (VIAGRA (TM)), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett. 1996;6:1819–24.
Teixeira CE, Priviero FBM, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther. 2006;316:654–61.
Savai R, Pullamsetti SS, Banat G-A, Weissmann N, Ghofrani HA, Grimminger F, et al. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs. 2010;19:117–31.
Lin C-S, Lau A, Tu R, Lue TF. Expression of three isoforms of cGMP-binding cGMP-specific Phosphodiesterase (PDE5) in human penile Cavernosum. Biochem Biophys Res Commun. 2000;268:628–35.
Guazzi M. Clinical use of Phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail. 2008;1:272–80.
Trochu JN, Leblais V, Rautureau Y, Bévérelli F, Le Marec H, Berdeaux A, et al. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol. 1999;128:69–76.
Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, Guillier F, Leroux V, et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J. 2010;24:1506–17.
Dabiré H, Barthélémy I, Blanchard-Gutton N, Sambin L, Sampedrano CC, Gouni V, et al. Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS. Basic Res Cardiol. 2012;107:1–9.
Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, Smith RJ, et al. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther. 1990;255:756–68.
Ong W-Y, Farooqui T, Kokotos G, Farooqui AA. Synthetic and natural inhibitors of phospholipases a (2): their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci. 2015;6:814–31.
Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990;101:746–52.
Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001;15:801–20.
Patrignani P, Patrono C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim Biophys Acta. 1851;2015:422–32.
Griffoni C, Spisni E, Strillacci A, Toni M, Bachschmid MM, Tomasi V. Selective inhibition of prostacyclin synthase activity by rofecoxib. J Cell Mol Med. 2007;11:327–38.
Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci. 1996;93:1480–5.
Olson LJ, Knych ET, Herzig TC, Drewett JG. Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation. Hypertension. 1997;29:254–61.
Zhao Y, Brandish PE, DiValentin M, Schelvis JPM, Babcock GT, Marletta MA. Inhibition of soluble Guanylate Cyclase by ODQ†. Biochemistry. 2000;39:10848–54.
Leung HS, Leung FP, Yao X, Ko WH, Chen Z-Y, Vanhoutte PM, et al. Endothelial mediators of the acetylcholine-induced relaxation of the rat femoral artery. Vasc Pharmacol. 2006;44:299–308.
Cosson E, Herisse M, Laude D, Thomas F, Valensi PE, Attali JR, et al. Aortic stiffness and pulse pressure amplification in Wistar-Kyoto and spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;292:H2506–12.
Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995;25:1111–5.
Shimokawa H, Matoba T. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pharmacol Res Off J Ital Pharmacol Soc. 2004;49:543–9.
Félétou M, Vanhoutte PM. EDHF: an update. Clin Sci. 2009;117:139–55.
Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res. 2009;15:5947–9.
Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15:6250–7.
Akutsu N, Sasaki S, Takagi H, Motoya M, Shitani M, Igarashi M, et al. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol. 2015;20:105–10.
Li Y, Gao Z-H, Qu X-J. The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol. 2015;116:216–21.
Sharabi FM, Daabees TT, El-Metwally MA, Senbel AM. Effect of sildenafil on the isolated rat aortic rings. Fundam Clin Pharmacol. 2005;19:449–56.
Berk BC, Alexander RW. Vasoactive effects of growth factors. Biochem Pharmacol. 1989;38:219–25.
Sauro MD, Thomas B. Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s). J Pharmacol Exp Ther. 1993;267:1119–25.
Florian JA, Watts SW. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Phys. 1999;276:H976–83.
Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors? Can J Physiol Pharmacol. 2007;85:97–104.
Santos NP, Colaço AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma research: a review. Tumour Biol. 2017;39:1010428317695923.